Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.

[1]  Sigrid Stroobants,et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.

[2]  J. Verweij,et al.  STI571: a magic bullet? , 2001, European journal of cancer.

[3]  Schaller Jl,et al.  Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. , 2001 .

[4]  P. D. Dal Cin,et al.  Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. , 2001, Cancer research.

[5]  K. Ishihara,et al.  Possible participation of a JAK2 signaling pathway in recombinant rat interleukin-5-induced prolongation of rat eosinophil survival. , 2001, Biochimica et biophysica acta.

[6]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[7]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[8]  M. Meyers,et al.  Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer. , 2001, Urology.

[9]  F. Levi-Schaffer,et al.  Human peripheral blood eosinophils express stem cell factor. , 2001, Blood.

[10]  B. Druker,et al.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[11]  R. Salgia,et al.  Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571 , 2000, Oncogene.

[12]  Ming-Shyue Lee,et al.  Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells , 2000, Oncogene.

[13]  V. Tonk,et al.  Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, literature review, and report of a case with a unique chromosomal abnormality. , 1998, Cancer genetics and cytogenetics.

[14]  T. Adachi,et al.  The mechanism of IL-5 signal transduction. , 1998, The American journal of physiology.

[15]  R. Garofalo,et al.  Lyn, Jak2, and Raf-1 Kinases Are Critical for the Antiapoptotic Effect of Interleukin 5, whereas only Raf-1 Kinase Is Essential for Eosinophil Activation and Degranulation , 1998, The Journal of experimental medicine.

[16]  M. Heidtman,et al.  Human Peripheral Blood Eosinophils Express a Functional c-kit Receptor for Stem Cell Factor that Stimulates Very Late Antigen 4 (VLA-4)–mediated Cell Adhesion to Fibronectin and Vascular Cell Adhesion Molecule 1 (VCAM-1) , 1997, The Journal of experimental medicine.

[17]  S. Zhao,et al.  2-Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome , 1997, Leukemia.

[18]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[19]  T. Spitzer,et al.  Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome , 1996, American journal of hematology.

[20]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.

[21]  G. Gleich,et al.  Interferon- Treatment of Six Patients with the Idiopathic Hypereosinophilic Syndrome , 1994, Annals of Internal Medicine.

[22]  G. Bubley,et al.  The idiopathic hypereosinophilic syndrome. , 1994, Blood.

[23]  Todd R. Golub,et al.  Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation , 1994, Cell.

[24]  M. Goldman,et al.  Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. , 1994, The New England journal of medicine.

[25]  M. Copin,et al.  Synthesis of interleukin-5 by activated eosinophils in patients with eosinophilic heart diseases. , 1993, Blood.

[26]  H. Kobayashi.  Effect of c-kit ligand (stem cell factor) in combination with interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3, on eosinophil lineage. , 1993, International journal of hematology.

[27]  C. Sanderson.  Interleukin-5, Eosinophils, and Disease , 1992 .

[28]  M. K. Bach,et al.  Activation of human eosinophils by platelet-derived growth factor. , 1992, International archives of allergy and immunology.

[29]  G. Hicks,et al.  Mitral valve replacement in idiopathic hypereosinophilic syndrome. , 1991, The Annals of thoracic surgery.

[30]  P. Degoulet,et al.  [Prognostic factors of hypereosinophilic syndrome. Study of 40 cases]. , 1989, Annales de medecine interne.

[31]  C. Guillaume,et al.  Hypereosinophilic syndrome with multiple organ dysfunction treated by allogeneic bone marrow transplantation , 1988, American journal of hematology.

[32]  C. Oakley,et al.  Clinical features of fifteen patients with the hypereosinophilic syndrome. , 1983, The Quarterly journal of medicine.

[33]  H. Gralnick,et al.  NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. , 1982, Annals of internal medicine.

[34]  A. Fauci,et al.  Therapy of the hypereosinophilic syndrome. , 1978, Annals of internal medicine.

[35]  S. Wolff,et al.  THE HYPEREOSINOPHILIC SYNDROME: Analysis of Fourteen Cases With Review of The Literature , 1975, Medicine.